Cryoglobulinemic Vasculitis (CryoVas): Comprehensive Disease Characteristics Report

Executive summary

Cryoglobulinemic vasculitis (CryoVas; also written “cryoglobulinaemic vasculitis”) is a systemic small-vessel vasculitis driven by circulating cryoglobulins—immunoglobulins that precipitate below 37 °C and resolubilize on warming—and consequent vascular immune-complex deposition and complement activation/consumption in mixed forms. The clinical spectrum ranges from the classic Meltzer triad (purpura, arthralgia, weakness) to life-/organ-threatening renal and neurologic disease. HCV historically accounted for most mixed CryoVas, but the DAA era has shifted the etiologic landscape toward autoimmune disease and lymphoproliferative disorders in many settings. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

1. Disease Information

1.1 Definition and current understanding

• Cryoglobulins are “immunoglobulins that reversibly precipitate at temperatures below 37 °C” (definition used in modern reviews). (dammacco2023thewidespectrum pages 1-3)
• Cryoglobulinemic vasculitis (CryoVas/CV) refers to a systemic vasculitic syndrome associated with cryoglobulin-containing immune complexes (mixed types) or cryoprotein-mediated vascular occlusion/hyperviscosity (type I), with manifestations from palpable purpura to severe neuropathy and glomerulonephritis. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3)

1.2 Common synonyms / alternative names

• Cryoglobulinemic vasculitis; cryoglobulinaemic vasculitis (British spelling). (vita2011preliminaryclassificationcriteria pages 1-1)
• Mixed cryoglobulinemic syndrome (MCS) / mixed cryoglobulinemia syndrome (used interchangeably in some clinical literature). (ferri2026cryoglobulinemiamonoclonaland pages 4-5)
• Cryoglobulinemic syndrome / mixed cryoglobulinemia (often used historically; nomenclature harmonization has been proposed to distinguish lab finding vs clinical syndrome). (ferri2026cryoglobulinemiamonoclonaland pages 4-5, ferri2008orphanetjournalof pages 2-4)

1.3 Key identifiers (ICD/MeSH/MONDO/Orphanet)

Within the retrieved full-text corpus, formal ICD-10/ICD-11, MeSH, MONDO, and Orphanet ORPHA identifiers were not explicitly stated. The report therefore cannot provide evidence-backed codes from the available documents. (Limitation of current evidence set.)

1.4 Evidence source type

This report is derived from aggregated disease-level resources (systematic/narrative reviews, consensus recommendations, and classification-criteria studies) and selected cohort studies, rather than EHR-derived individual case aggregation. (dammacco2023thewidespectrum pages 1-3, rajendran2023riskfactorsfor pages 1-2, vita2011preliminaryclassificationcriteria pages 5-6)

2. Etiology

2.1 Primary causal factors / associated diseases

Cryoglobulinemia/CryoVas is etiologically heterogeneous, with major associated categories: 1. Infectious: especially hepatitis C virus (HCV) historically; also HBV and other infections. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5, mazzaro2023hepatitisbvirusinfection pages 1-2) 2. Autoimmune disease: e.g., Sjögren’s syndrome, systemic lupus erythematosus (SLE). (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5, roubertou2022cryoglobulinemiainsystemic pages 1-2) 3. B-cell lymphoproliferative disorders: dominant in type I cryoglobulinemia and important in mixed CryoVas (including risk of NHL). (ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5, dammacco2023thewidespectrum pages 1-3)

2.2 Classification (etiology-relevant)

Cryoglobulins are commonly classified by Brouet type: * Type I: single monoclonal Ig, associated with B-cell lymphoproliferative disorders. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3) * Type II (mixed): monoclonal IgM with RF activity + polyclonal IgG. (dammacco2023thewidespectrum pages 1-3) * Type III (mixed): polyclonal IgM/IgG. (dammacco2023thewidespectrum pages 1-3)

2.3 Risk factors (selected quantitative)

• In type I cryoglobulinemia, >90% have an underlying lymphoproliferative disorder; MGUS frequency 36%–86%, overt hematologic malignancy 20%–64%. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)
• In mixed CryoVas, HCV markers have historically been present in the majority of cases; one review notes anti-HCV positivity ranges widely across series. (cacoub2002cryoglobulinemiavasculitis. pages 2-3, dammacco2023thewidespectrum pages 1-3)

2.4 Protective factors

Evidence for explicit “protective factors” (genetic or environmental) was not identified in the retrieved corpus.

2.5 Gene–environment interactions

Mechanistic gene–environment interaction evidence (e.g., specific susceptibility loci interacting with infections) was not identified in the retrieved corpus.

3. Phenotypes

3.1 Core phenotype spectrum

• Meltzer triad: purpura, arthralgia, weakness. (dammacco2023thewidespectrum pages 1-3, covic2023therapeuticpotentialof pages 1-3)
• Cutaneous: palpable purpura; ulcers; digital ischemia; livedo; Raynaud phenomenon (not exhaustive). (covic2023therapeuticpotentialof pages 1-3, roubertou2022cryoglobulinemiainsystemic pages 1-2)
• Neurologic: peripheral neuropathy; potentially severe neuropathy; occasional CNS involvement. (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3, roubertou2022cryoglobulinemiainsystemic pages 1-2)
• Renal: membranoproliferative glomerulonephritis / cryoglobulinemic glomerulonephritis. (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3)

3.2 Frequency / severity (examples)

• In an SLE cohort screened for cryoglobulins, 15% of cryoglobulin-positive patients developed CryoVas; severe manifestations were uncommon (GN 5%, CNS involvement 19%) with no deaths reported during follow-up. (roubertou2022cryoglobulinemiainsystemic pages 1-2)
• In non-infectious CryoVas, relapse rates reported as ~28% in type I and 22%–60% in mixed NICV, with time-to-relapse 1–80 months. (rajendran2023riskfactorsfor pages 1-2)

3.3 Suggested HPO terms (examples; ontology suggestions)

(These are suggested mappings; the retrieved sources do not provide HPO IDs.) * Palpable purpura; skin ulcer; arthralgia; fatigue/asthenia; peripheral neuropathy; glomerulonephritis; Raynaud phenomenon; digital ischemia.

4. Genetic/Molecular Information

4.1 Causal genes / pathogenic variants

CryoVas is not primarily a monogenic disorder in typical adult presentations; the retrieved evidence emphasizes secondary causes (infection, autoimmunity, lymphoproliferation). Specific causal germline variants were not identified in the retrieved corpus. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

4.2 Molecular features highlighted in recent literature

• Mixed CryoVas pathogenesis includes B-cell aberrant lymphoproliferation and autoantibody (RF) production, leading to immune complex formation and deposition. (ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

5. Environmental Information

5.1 Infectious agents

• HCV is the dominant historical driver of mixed cryoglobulinemia/CryoVas; cryoglobulins are detectable in ~25–30% of HCV-infected individuals in one major review. (dammacco2023thewidespectrum pages 1-3)
• HBV can cause CryoVas; European series estimate HBV-associated CryoVas prevalence among HBV patients 0.5%–5.5% (reviewed literature). (mazzaro2023hepatitisbvirusinfection pages 1-2)

5.2 Lifestyle/occupational exposures

Specific environmental toxin/lifestyle causal associations were not identified in the retrieved corpus.

6. Mechanism / Pathophysiology

6.1 Causal chain (high-level)

1. Trigger/driver: chronic infection (esp. HCV historically), autoimmune disease, or monoclonal B-cell disorder. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)
2. B-cell dysregulation with RF activity and production of cryoprecipitable immunoglobulins (mixed types). (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)
3. Immune complex formation and deposition in small vessels → leukocytoclastic vasculitis and end-organ damage (skin, nerves, kidneys). (ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3)
4. Complement consumption (often low C4) and systemic inflammation. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

Type I differs mechanistically, tending toward mechanical vascular occlusion/hyperviscosity rather than classic immune-complex vasculitis. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

6.2 Suggested GO/CL terms (examples; ontology suggestions)

• GO biological processes: immune complex clearance; complement activation; B cell activation; leukocyte migration; vasculitis/inflammatory response.
• CL cell types: B cell; plasma cell; neutrophil; monocyte/macrophage; endothelial cell.

7. Anatomical Structures Affected

7.1 Organ/tissue involvement

• Skin (purpura, ulcers, digital ischemia). (dammacco2023thewidespectrum pages 1-3, roubertou2022cryoglobulinemiainsystemic pages 1-2)
• Peripheral nervous system (peripheral neuropathy). (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3)
• Kidney (membranoproliferative glomerulonephritis). (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3)

7.2 Suggested UBERON terms (examples; ontology suggestions)

Skin; peripheral nerve; kidney glomerulus; small blood vessel.

8. Temporal Development

8.1 Onset/course

• Typical onset is adult (reviews cite age ranges such as 45–65 in NICV contexts). (rajendran2023riskfactorsfor pages 2-3)
• Course can be relapsing; relapse timing reported from 1 to 80 months in NICV. (rajendran2023riskfactorsfor pages 1-2)

9. Inheritance and Population

9.1 Epidemiology

• Essential mixed cryoglobulinemia prevalence reported as ~1:100,000 and female:male ratio ~3:1 in an Orphanet-style review article. (ferri2008orphanetjournalof pages 1-2)
• In HCV infection, cryoglobulin positivity varies widely by cohort; a large HCV prospective cohort found mixed cryoglobulin in 40%. (cacoub2002cryoglobulinemiavasculitis. pages 2-3)
• Severe symptomatic vasculitis is relatively uncommon among cryoglobulin-positive HCV patients; one review notes only ~2–3% develop severe vasculitis. (cacoub2002cryoglobulinemiavasculitis. pages 2-3)

9.2 Geographic distribution

Higher frequency in Southern Europe versus Northern Europe/North America is reported in older epidemiologic summaries. (ferri2008orphanetjournalof pages 1-2)

10. Diagnostics

10.1 Classification criteria (De Vita et al.)

The De Vita 2011 classification framework requires (i) documented cryoglobulins and (ii) positivity in at least 2 of 3 domains (questionnaire, clinical, laboratory), with reported sensitivity ~88.5% and specificity ~93.6% in key comparisons. (vita2011preliminaryclassificationcriteria pages 5-6, vita2011preliminaryclassificationcriteria pages 1-1)

A cropped figure from the original paper is available and summarizes the domains and thresholds. (vita2011preliminaryclassificationcriteria media 2dc84f3a)

10.2 Laboratory testing: cryoglobulin pre-analytics (critical for avoiding false negatives)

Multiple laboratory best-practice sources emphasize that cryoglobulin testing is highly sensitive to pre-analytical temperature control: * Maintain whole blood at ~37 °C from collection through clotting and serum separation; use pre-warmed tubes and warm transport (e.g., thermos). (sargur2010cryoglobulinevaluationbest pages 4-5, motyckova2011laboratorytestingfor pages 1-2, bakker2003adequatesamplingin pages 1-2) * Typical protocols include clotting at 37 °C for ~1 hour, separation (preferably warm centrifugation), then serum incubation at 4 °C for 3–7 days to allow precipitation (type II/III may take up to a week). (sargur2010cryoglobulinevaluationbest pages 4-5, motyckova2011laboratorytestingfor pages 2-3, patel2024evaluationofcryoprotein pages 5-6) * Insufficient volume (e.g., <10 mL) and temperature drops can cause false negatives. (mariscalrodriguez2019laboratoryguidelinesfor pages 4-5)

10.3 Common supportive biomarkers/tests

• Low complement (esp. low C4) and RF positivity are common in mixed CryoVas and are part of classification laboratory domains. (vita2011preliminaryclassificationcriteria pages 3-4)
• Demonstration of cryoglobulin type (immunofixation) is essential to distinguish type I versus mixed and guide etiologic work-up. (dammacco2023thewidespectrum pages 1-3, motyckova2011laboratorytestingfor pages 2-3)

10.4 Differential diagnosis (high-level)

CryoVas is within immune-complex small-vessel vasculitis differential; formal differentials were not comprehensively extractable from the retrieved corpus.

11. Outcome / Prognosis

11.1 Survival/mortality

• A DAA-era narrative synthesis reports mortality about ~25% at 5 years and ~40% at 10 years for HCV-associated CryoVas; and 10-year survival differences by subtype (HCV-positive mixed 63%, HCV-negative mixed 65%, type I 87%)—these estimates should be interpreted cautiously as they are review-level summaries rather than a single prospective cohort. (balta2025impactofdirectacting pages 5-6)

11.2 Relapse and prognostic factors

• NICV relapse rates: ~28% in type I and 22–60% in mixed NICV (systematic review). (rajendran2023riskfactorsfor pages 1-2)
• Factors associated with relapse/death in NICV syntheses include incomplete immunologic response (e.g., failure to normalize C4 and reduce/disappear cryoglobulins), and severe organ involvement (e.g., renal insufficiency, pulmonary/GI involvement) and older age. (rajendran2023riskfactorsfor pages 1-2, rajendran2023riskfactorsfor pages 2-3)

12. Treatment

12.1 Current standard approaches (real-world implementation)

Treatment is commonly framed as a three-pronged strategy: 1. Treat underlying cause (e.g., antivirals for HCV; nucleos(t)ide analogues for HBV). (covic2023therapeuticpotentialof pages 1-3, mazzaro2023hepatitisbvirusinfection pages 1-2) 2. B-cell–targeted therapy (rituximab) for moderate–severe disease, persistent disease after viral clearance, contraindications to antivirals, or organ-/life-threatening manifestations. (dammacco2023thewidespectrum pages 1-3, covic2023therapeuticpotentialof pages 1-3) 3. Plasma exchange/apheresis and intensive immunosuppression (high-dose glucocorticoids ± cyclophosphamide) for emergencies such as hyperviscosity or severe organ-threatening disease. (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3)

12.2 Antiviral therapy in HCV-associated CryoVas

• Direct-acting antivirals (DAAs) are recommended broadly for HCV-positive CryoVas and achieve high SVR at population level; CryoVas manifestation resolution rates are variable across studies. (dammacco2023thewidespectrum pages 1-3, dammacco2023thewidespectrum pages 3-5)

12.3 Rituximab (anti-CD20)

• Evidence syntheses indicate rituximab can induce remission in many mixed CryoVas patients and is used especially for severe disease or DAA-nonresponders/persistent vasculitis. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3)
• In HCV-associated CryoVas, a systematic review reports trial-level results where rituximab achieved remission in 83.3% at 6 months in one trial compared with 8.3% control; and improved sustained response in combination with interferon-era antivirals. (covic2023therapeuticpotentialof pages 1-3)

12.4 Glucocorticoids and cyclophosphamide

• Glucocorticoids may mitigate vasculitis acutely but are not considered maintenance therapy in some expert syntheses; cyclophosphamide use has been largely replaced by rituximab but remains relevant in severe cases. (dammacco2023thewidespectrum pages 1-3)

12.5 Plasma exchange / apheresis

• Therapeutic apheresis is described as an emergency treatment in hyperviscosity syndrome. (dammacco2023thewidespectrum pages 1-3)

12.6 Emerging / experimental therapies

Evidence in the retrieved corpus highlights potential rescue options in rituximab-refractory nonviral CryoVas, including alkylators and biologics (e.g., rituximab + belimumab in small series). (ezconde2023nonviralcryoglobulinemicvasculitis pages 14-16)

12.7 Suggested MAXO terms (examples; ontology suggestions)

Antiviral therapy; B-cell depletion therapy (anti-CD20); therapeutic plasma exchange; glucocorticoid therapy; alkylating agent chemotherapy.

13. Prevention

Primary prevention is largely indirect via prevention/treatment of underlying causes (e.g., HCV treatment and HBV suppression). Explicit prevention trial evidence was not identified in the retrieved corpus.

14. Other Species / Natural Disease

No evidence for naturally occurring CryoVas analogs in non-human species was identified in the retrieved corpus.

15. Model Organisms

No specific model-organism systems were identified in the retrieved corpus.

Visual evidence: De Vita classification criteria figure

The following figure excerpt summarizes the three-domain De Vita classification criteria and the requirement for repeated cryoglobulin positivity. (vita2011preliminaryclassificationcriteria media 2dc84f3a)

Direct abstract quotes (selected)

• Dammacco et al. 2023 (Clin Exp Med; published Mar 2023; https://doi.org/10.1007/s10238-022-00808-1): “Immunoglobulins that reversibly precipitate at temperatures below 37 °C are called cryoglobulins (CGs). Cryoglobulinemia often manifests as cryoglobulinemic vasculitis (CV), whose symptoms range in severity from purpuric eruptions to life-threatening features.” (dammacco2023thewidespectrum pages 1-3)
• De Vita et al. 2011 (Ann Rheum Dis; published Jul 2011; https://doi.org/10.1136/ard.2011.150755): “Positivity of serum cryoglobulins was defined by experts as an essential condition for CV classification.” (vita2011preliminaryclassificationcriteria pages 1-1)

Evidence gaps / limitations

1. Ontology/identifier codes (MONDO, ORPHA, ICD, MeSH) were not explicitly present in the retrieved full-text evidence; adding them would require direct database queries beyond the current paper corpus.
2. Many quantitative outcome estimates for the DAA era are available mainly as review-level syntheses rather than uniformly reported prospective cohorts; where such estimates are used, they are attributed as such.
3. Genetic susceptibility loci, protective factors, and model organism data were not found in the retrieved sources.

References

1. (dammacco2023thewidespectrum pages 1-3): Franco Dammacco, Gianfranco Lauletta, and Angelo Vacca. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clinical and Experimental Medicine, 23:255-272, Mar 2023. URL: https://doi.org/10.1007/s10238-022-00808-1, doi:10.1007/s10238-022-00808-1. This article has 50 citations and is from a peer-reviewed journal.

2. (ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3): Andrea N úñ ez-Conde, Ignasi Rodr í guez-Pint ó, David A. Alba-Garibay, Alba Álvarez-Abella, Alba Jerez-Lienas, Oriol Llargu é s, M. Antonio, Alba-S á nchez, Diana Oleas, and Marco A Alba. Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice. Vessel Plus, Oct 2023. URL: https://doi.org/10.20517/2574-1209.2023.105, doi:10.20517/2574-1209.2023.105. This article has 3 citations.

3. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5): Andrea N úñ ez-Conde, Ignasi Rodr í guez-Pint ó, David A. Alba-Garibay, Alba Álvarez-Abella, Alba Jerez-Lienas, Oriol Llargu é s, M. Antonio, Alba-S á nchez, Diana Oleas, and Marco A Alba. Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice. Vessel Plus, Oct 2023. URL: https://doi.org/10.20517/2574-1209.2023.105, doi:10.20517/2574-1209.2023.105. This article has 3 citations.

4. (vita2011preliminaryclassificationcriteria pages 1-1): S. Vita, F. Soldano, Miriam Isola, Giuseppe Monti, A. Gabrielli, A. Tzioufas, C. Ferri, G. Ferraccioli, L. Quartuccio, L. Corazza, G. D. Marchi, M. R. Casals, M. Voulgarelis, Marco Lenzi, Francesco Saccardo, P. Fraticelli, M. Mascia, D. Sansonno, P. Cacoub, M. Tomšič, A. Tavoni, M. Pietrogrande, A. Zignego, S. Scarpato, C. Mazzaro, Pietro Pioltelli, Serge Steinfeld, P. Lamprecht, S. Bombardieri, and M. Galli. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases, 70:1183-1190, Jul 2011. URL: https://doi.org/10.1136/ard.2011.150755, doi:10.1136/ard.2011.150755. This article has 214 citations and is from a highest quality peer-reviewed journal.

5. (ferri2026cryoglobulinemiamonoclonaland pages 4-5): Clodoveo Ferri, Laura Gragnani, Anna Linda Zignego, and Dilia Giuggioli. Cryoglobulinemia, monoclonal and mixed cryoglobulinemia syndromes, cryoglobulinemic vasculitis: a proposal for comprehensive nomenclature and definition. Frontiers in Immunology, Feb 2026. URL: https://doi.org/10.3389/fimmu.2026.1754012, doi:10.3389/fimmu.2026.1754012. This article has 0 citations and is from a peer-reviewed journal.

6. (ferri2008orphanetjournalof pages 2-4): C Ferri. Orphanet journal of rare. Unknown journal, 2008.

7. (rajendran2023riskfactorsfor pages 1-2): Nithya Rajendran, Puteri Maisarah Rameli, and Hanaa Awad. Risk factors for relapse in non-infectious cryoglobulinemic vasculitis, including type i cryoglobulinemia: a systematic review. Frontiers in Immunology, Jul 2023. URL: https://doi.org/10.3389/fimmu.2023.1215345, doi:10.3389/fimmu.2023.1215345. This article has 4 citations and is from a peer-reviewed journal.

8. (vita2011preliminaryclassificationcriteria pages 5-6): S. Vita, F. Soldano, Miriam Isola, Giuseppe Monti, A. Gabrielli, A. Tzioufas, C. Ferri, G. Ferraccioli, L. Quartuccio, L. Corazza, G. D. Marchi, M. R. Casals, M. Voulgarelis, Marco Lenzi, Francesco Saccardo, P. Fraticelli, M. Mascia, D. Sansonno, P. Cacoub, M. Tomšič, A. Tavoni, M. Pietrogrande, A. Zignego, S. Scarpato, C. Mazzaro, Pietro Pioltelli, Serge Steinfeld, P. Lamprecht, S. Bombardieri, and M. Galli. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases, 70:1183-1190, Jul 2011. URL: https://doi.org/10.1136/ard.2011.150755, doi:10.1136/ard.2011.150755. This article has 214 citations and is from a highest quality peer-reviewed journal.

9. (mazzaro2023hepatitisbvirusinfection pages 1-2): Cesare Mazzaro, Riccardo Bomben, Marcella Visentini, Laura Gragnani, Luca Quartuccio, Francesco Saccardo, Marco Sebastiani, Davide Filippini, Gianfranco Lauletta, Giuseppe Monti, and Valter Gattei. Hepatitis b virus-infection related cryoglobulinemic vasculitis. clinical manifestations and the effect of antiviral therapy: a review of the literature. Frontiers in Oncology, Feb 2023. URL: https://doi.org/10.3389/fonc.2023.1095780, doi:10.3389/fonc.2023.1095780. This article has 12 citations.

10. (roubertou2022cryoglobulinemiainsystemic pages 1-2): Yoann Roubertou, Sabine Mainbourg, Arnaud Hot, Denis Fouque, Cyrille Confavreux, Roland Chapurlat, Sébastien Debarbieux, Denis Jullien, Pascal Sève, Laurent Juillard, Marie-Nathalie Kolopp-Sarda, and Jean-Christophe Lega. Cryoglobulinemia in systemic lupus erythematosus: a retrospective study of 213 patients. Arthritis Research & Therapy, Jul 2022. URL: https://doi.org/10.1186/s13075-022-02857-z, doi:10.1186/s13075-022-02857-z. This article has 18 citations and is from a domain leading peer-reviewed journal.

11. (cacoub2002cryoglobulinemiavasculitis. pages 2-3): Patrice Cacoub, Nathalie Costedoat-Chalumeau, Olivier Lidove, and Laurent Alric. Cryoglobulinemia vasculitis. Current opinion in rheumatology, 14 1:29-35, Jan 2015. URL: https://doi.org/10.1097/00002281-200201000-00006, doi:10.1097/00002281-200201000-00006. This article has 354 citations and is from a peer-reviewed journal.

12. (covic2023therapeuticpotentialof pages 1-3): Andreea Covic, Irina Draga Caruntu, Alexandru Burlacu, Simona Eliza Giusca, Adrian Covic, Anca Elena Stefan, Crischentian Brinza, and Gener Ismail. Therapeutic potential of rituximab in managing hepatitis c-associated cryoglobulinemic vasculitis: a systematic review. Journal of Clinical Medicine, 12:6806, Oct 2023. URL: https://doi.org/10.3390/jcm12216806, doi:10.3390/jcm12216806. This article has 7 citations.

13. (rajendran2023riskfactorsfor pages 2-3): Nithya Rajendran, Puteri Maisarah Rameli, and Hanaa Awad. Risk factors for relapse in non-infectious cryoglobulinemic vasculitis, including type i cryoglobulinemia: a systematic review. Frontiers in Immunology, Jul 2023. URL: https://doi.org/10.3389/fimmu.2023.1215345, doi:10.3389/fimmu.2023.1215345. This article has 4 citations and is from a peer-reviewed journal.

14. (ferri2008orphanetjournalof pages 1-2): C Ferri. Orphanet journal of rare. Unknown journal, 2008.

15. (vita2011preliminaryclassificationcriteria media 2dc84f3a): S. Vita, F. Soldano, Miriam Isola, Giuseppe Monti, A. Gabrielli, A. Tzioufas, C. Ferri, G. Ferraccioli, L. Quartuccio, L. Corazza, G. D. Marchi, M. R. Casals, M. Voulgarelis, Marco Lenzi, Francesco Saccardo, P. Fraticelli, M. Mascia, D. Sansonno, P. Cacoub, M. Tomšič, A. Tavoni, M. Pietrogrande, A. Zignego, S. Scarpato, C. Mazzaro, Pietro Pioltelli, Serge Steinfeld, P. Lamprecht, S. Bombardieri, and M. Galli. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases, 70:1183-1190, Jul 2011. URL: https://doi.org/10.1136/ard.2011.150755, doi:10.1136/ard.2011.150755. This article has 214 citations and is from a highest quality peer-reviewed journal.

16. (sargur2010cryoglobulinevaluationbest pages 4-5): Ravishankar Sargur, Peter White, and William Egner. Cryoglobulin evaluation: best practice? Annals of Clinical Biochemistry, 47:16-8, Jan 2010. URL: https://doi.org/10.1258/acb.2009.009180, doi:10.1258/acb.2009.009180. This article has 153 citations and is from a peer-reviewed journal.

17. (motyckova2011laboratorytestingfor pages 1-2): Gabriela Motyckova and Mandakolathur Murali. Laboratory testing for cryoglobulins. American Journal of Hematology, 86:500-502, Jun 2011. URL: https://doi.org/10.1002/ajh.22023, doi:10.1002/ajh.22023. This article has 136 citations and is from a domain leading peer-reviewed journal.

18. (bakker2003adequatesamplingin pages 1-2): Andries J. Bakker, Jennichjen Slomp, Taede de Vries, Dick A.G. Boymans, Bert Veldhuis, Kees Halma, and Peter Joosten. Adequate sampling in cryoglobulinaemia: recommended warmly. Clinical Chemistry and Laboratory Medicine, 41:85-89, Jan 2003. URL: https://doi.org/10.1515/cclm.2003.015, doi:10.1515/cclm.2003.015. This article has 29 citations and is from a peer-reviewed journal.

19. (motyckova2011laboratorytestingfor pages 2-3): Gabriela Motyckova and Mandakolathur Murali. Laboratory testing for cryoglobulins. American Journal of Hematology, 86:500-502, Jun 2011. URL: https://doi.org/10.1002/ajh.22023, doi:10.1002/ajh.22023. This article has 136 citations and is from a domain leading peer-reviewed journal.

20. (patel2024evaluationofcryoprotein pages 5-6): Dina Patel, Ravishankar Sargur, Joanna Sheldon, Rachel D Wheeler, and Carol Stanley. Evaluation of cryoprotein investigation using a digital external quality assurance scheme. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 61:347-355, Mar 2024. URL: https://doi.org/10.1177/00045632241239805, doi:10.1177/00045632241239805. This article has 3 citations.

21. (mariscalrodriguez2019laboratoryguidelinesfor pages 4-5): A. Mariscal-Rodríguez, L.M. Villar Guimerans, M. López-Trascasa, M. Hernández González, and E. Moga Naranjo. Laboratory guidelines for the diagnosis of patients with cryoglobulinemic syndrome. Revista Clinica Espanola, 219:505-513, Dec 2019. URL: https://doi.org/10.1016/j.rceng.2019.01.003, doi:10.1016/j.rceng.2019.01.003. This article has 6 citations and is from a peer-reviewed journal.

22. (vita2011preliminaryclassificationcriteria pages 3-4): S. Vita, F. Soldano, Miriam Isola, Giuseppe Monti, A. Gabrielli, A. Tzioufas, C. Ferri, G. Ferraccioli, L. Quartuccio, L. Corazza, G. D. Marchi, M. R. Casals, M. Voulgarelis, Marco Lenzi, Francesco Saccardo, P. Fraticelli, M. Mascia, D. Sansonno, P. Cacoub, M. Tomšič, A. Tavoni, M. Pietrogrande, A. Zignego, S. Scarpato, C. Mazzaro, Pietro Pioltelli, Serge Steinfeld, P. Lamprecht, S. Bombardieri, and M. Galli. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases, 70:1183-1190, Jul 2011. URL: https://doi.org/10.1136/ard.2011.150755, doi:10.1136/ard.2011.150755. This article has 214 citations and is from a highest quality peer-reviewed journal.

23. (balta2025impactofdirectacting pages 5-6): Alexia Anastasia Stefania Balta, Mariana Daniela Ignat, Raisa Eloise Barbu, Caterina Dumitru, Diana Sabina Radaschin, Valentin Bulza, Silvia Aura Mateescu Costin, Catalin Pleșea-Condratovici, and Liliana Baroiu. Impact of direct-acting antivirals on extrahepatic manifestations in chronic hepatitis c: a narrative review with a hermeneutic approach. Healthcare, 13:1953, Aug 2025. URL: https://doi.org/10.3390/healthcare13161953, doi:10.3390/healthcare13161953. This article has 4 citations.

24. (dammacco2023thewidespectrum pages 3-5): Franco Dammacco, Gianfranco Lauletta, and Angelo Vacca. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clinical and Experimental Medicine, 23:255-272, Mar 2023. URL: https://doi.org/10.1007/s10238-022-00808-1, doi:10.1007/s10238-022-00808-1. This article has 50 citations and is from a peer-reviewed journal.

25. (ezconde2023nonviralcryoglobulinemicvasculitis pages 14-16): Andrea N úñ ez-Conde, Ignasi Rodr í guez-Pint ó, David A. Alba-Garibay, Alba Álvarez-Abella, Alba Jerez-Lienas, Oriol Llargu é s, M. Antonio, Alba-S á nchez, Diana Oleas, and Marco A Alba. Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice. Vessel Plus, Oct 2023. URL: https://doi.org/10.20517/2574-1209.2023.105, doi:10.20517/2574-1209.2023.105. This article has 3 citations.